Evidence map›Paper›PMID 30939480›Full record

Trial reportAmerican journal of nephrology2019

Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.

Brad P Dieter, Kenn B Daratha, Sterling M McPherson, Robert Short, Radica Z Alicic, Katherine R Tuttle

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Characterization of features and outcomes of young patients (< 45 years) presenting with ST-segment elevation myocardial infarction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Brad P DieterProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA, braddieter@gmail.com.
Kenn B DarathaProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA.
Sterling M McPhersonProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA.
Robert ShortProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA.
Radica Z AlicicProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA.
Katherine R TuttleProvidence Medical Research Center, Providence Health Care, Spokane, Washington, USA.

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1DUC4DK101108 · NIDDK · JOSLIN DIABETES CENTER · PI DORIA, ALESSANDRO, MAUER, S. MICHAEL · 2013 to 2018
$31.6M
Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
ConProject-002U2CDK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI KRETZLER, MATTHIAS · 2017 to 2021
$21.0M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2009 to 2023
$20.3M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Medication Intervention in Transitional Care to Optimize CKD Outcomes & CostsR34DK094016 · NIDDK · SACRED HEART MEDICAL CENTER · PI CORBETT, CINDY LOU, TUTTLE, KATHERINE R · 2011 to 2012
$621k
NCATS NIH HHS UL1 TR000043NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR002319NIDDK NIH HHS R34 DK094016NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U2C DK114886NIDDK NIH HHS U54 DK083912NIDDK NIH HHS UC4 DK101108NIDDK NIH HHS UM1 DK100846
6 · The paper itself

Abstract

RATIONALE AND

objectiveIn the Systolic Blood Pressure Intervention Trial, the possible relationships between acute kidney injury (AKI) and risk of major cardiovascular events and death are not known. STUDY

designPost hoc analysis of a multicenter, randomized, controlled, open-label clinical trial. SETTING AND

participantsHypertensive adults without diabetes who were ≥50 years of age with prior cardiovascular disease, chronic kidney disease (CKD), 10-year Framingham risk score > 15%, or age > 75 years were assigned to a systolic blood pressure target of < 120 mm Hg (intensive) or < 140 mm Hg (standard). PREDICTOR: AKI episodes. OUTCOMES: The primary outcome was a composite of myocardial infarction, acute coronary syndrome, stroke, decompensated heart failure, or cardiovascular death. The secondary outcome was death from any cause. Analytical Approach: AKI was defined using the Kidney Disease: Improving Global Outcomes modified criteria based solely upon serum creatinine. AKI episodes were identified by serious adverse events or emergency room visits. Cox proportional hazards models assessed the risk for the primary and secondary outcomes by AKI status.

resultsParticipants were 68 ± 9 years of age, 36% women (3,332/9,361), and 30% Black race (2,802/9,361), and 17% (1,562/9,361) with cardiovascular disease. Systolic blood pressure was 140 ± 16 mm Hg at study entry. AKI occurred in 4.4% (204/4,678) and 2.6% (120/4,683) in the intensive and standard treatment groups respectively (p < 0.001). Those who experienced AKI had higher risk of cardiovascular events (hazard ratio [HR] 1.52, 95% CI 1.05-2.20, p = 0.026) and death from any cause (HR 2.33, 95% CI 1.56-3.48, p < 0.001) controlling for age, sex, race, baseline systolic blood pressure, body mass index, number of antihypertensive medications, cardiovascular disease and CKD status, hypotensive episodes, and treatment assignment. LIMITATIONS: The study was not prospectively designed to determine relationships between AKI, cardiovascular events, and death.

conclusionsAmong older adults with hypertension at high cardiovascular risk, intensive treatment of blood pressure independently increased risk of AKI, which substantially raised risks of major cardiovascular events and death.

Indexed as

Cause of DeathAcute Kidney InjuryAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCardiovascular DiseasesFemaleFollow-Up StudiesHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedRisk FactorsAntihypertensive AgentsAnti-hypertensive treatmentBlood pressureHypertensionKidney diseaseSurvival

Identifiers

PMID30939480
PMCPMC7765707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.